Wegovy, the weight-loss brand of semaglutide, has a recommended maintenance dose of 2.4 mg. Novo ran the Phase III STEP UP ...
In the ongoing quest to expand semaglutide’s clinical pedigree and cement the GLP-1's market position, Novo Nordisk is ...
People who stayed on a 7.2 milligram weekly dose of semaglutide lost around 20% of their body weight over 72 weeks.
Eli Lilly and its rivals are working to develop more convenient options than the injectable Zepbound and Wegovy, which ...
We meet some of the first NHS patients, as expert says funding everyone eligible would "bankrupt" the service.
New tests may show how much value a particular obese patient will get for a GLP-1 agonist prescription dollar.
Ozempic has been approved for diabetes, though it's sometimes still used for weight loss. Rybelsus is a similar drug that's the same price and uses the same ingredient as Ozempic. But Rybelsus is ...
Injectable GLP-1 agonists help people struggling to lose weight. Patients are finding the drug also helps reduce recurring ...
The key drugs in the weight-loss injection market are Ozempic, Wegovy and Mounjaro. Understandably, there has been a flurry of interest in knowing more about these drugs – the differences ...
Over the last year, weight loss jabs have become highly popular, particularly as the NHS began offering Wegovy in late 2023 and will start offering Mounjaro to patients in March 2025. There has ...
Results that may be inaccessible to you are currently showing.
Hide inaccessible results
Feedback